Mette Marie Rosenkilde

List of Publications by Year
in descending order

186	9,836	53794 45	43889 91
papers	citations	h-index	g-index

193	193	193	9149
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin. Journal of Heart and Lung Transplantation, 2022, 41, 287-297.	0.6	19
2	Expression Profile of the GLP-1 Receptor in the Gastrointestinal Tract and Pancreas in Adult Female Mice. Endocrinology, 2022, 163, .	2.8	8
3	Molecular and inÂvivo phenotyping of missense variants of the human glucagon receptor. Journal of Biological Chemistry, 2022, 298, 101413.	3.4	8
4	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	7.1	13
5	The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. European Journal of Endocrinology, 2022, 186, 207-221.	3.7	3
6	GLP-1 and GIP receptor signaling in beta cells â€“ A review of receptor interactions and co-stimulation. Peptides, 2022, 151, 170749.	2.4	29
7	Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails. International Journal of Molecular Sciences, 2022, 23, 1397.	4.1	3
8	GPR183 Is Dispensable for B1 Cell Accumulation and Function, but Affects B2 Cell Abundance, in the Omentum and Peritoneal Cavity. Cells, 2022, 11, 494.	4.1	3
9	Opposing roles of the entero-pancreatic hormone urocortin-3 in glucose metabolism in rats. Diabetologia, 2022, 65, 1018-1031.	6.3	2
10	A Blunted GPR183/Oxysterol Axis During Dysglycemia Results in Delayed Recruitment of Macrophages to the Lung During Mycobacterium tuberculosis Infection. Journal of Infectious Diseases, 2022, 225, 2219-2228.	4.0	14
11	The non-ELR CXC chemokine encoded by human cytomegalovirus UL146 genotype 5 contains a C-terminal Î²-hairpin and induces neutrophil migration as a selective CXCR2 agonist. PLoS Pathogens, 2022, 18, e1010355.	4.7	4
12	Identification of a conserved chemokine receptor motif that enables ligand discrimination. Science Signaling, 2022, 15, eabg7042.	3.6	2
13	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	4.4	5
14	Nâ€terminal alterations turn the gut hormone GLPâ€2 into an antagonist with gradual loss of GLPâ€2 receptor selectivity towards more GLPâ€1 receptor interaction. British Journal of Pharmacology, 2022, 179, 4473-4485.	5.4	5
15	Epstein-Barr Virus-Encoded BILF1 Orthologues From Porcine Lymphotropic Herpesviruses Display Common Molecular Functionality. Frontiers in Endocrinology, 2022, 13, .	3.5	1
16	Glucoseâ€dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat dietâ€fed mice. British Journal of Pharmacology, 2022, 179, 4486-4499.	5.4	7
17	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
18	The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology, 2021, 162, .	2.8	43

#	Article	IF	Citations
19	Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor. Structure, 2021, 29, 679-693.e6.	3.3	13
20	The frequency of cytomegalovirus non-ELR UL146 genotypes in neonates with congenital CMV disease is comparable to strains in the background population. BMC Infectious Diseases, 2021, 21, 386.	2.9	4
21	Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization. Communications Biology, 2021, 4, 569.	4.4	23
22	Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. Journal of the Endocrine Society, 2021, 5, bvab084.	0.2	18
23	Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E874-E885.	3.5	25
24	Mutational Landscape of the Proglucagon-Derived Peptides. Frontiers in Endocrinology, 2021, 12, 698511.	3.5	7
25	Structural basis for the constitutive activity and immunomodulatory properties of the Epstein-Barr virus-encoded G protein-coupled receptor BILF1. Immunity, 2021, 54, 1405-1416.e7.	14.3	18
26	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21
27	Discovery of GPR183 Agonists Based on an Antagonist Scaffold. ChemMedChem, 2021, 16, 2623-2627.	3.2	6
28	Multiple Targets for Oxysterols in Their Regulation of the Immune System. Cells, 2021, 10, 2078.	4.1	15
29	L-Cell Expression of Melanocortin-4-Receptor Is Marginal in Most of the Small Intestine in Mice and Humans and Direct Stimulation of Small Intestinal Melanocortin-4-Receptors in Mice and Rats Does Not Affect GLP-1 Secretion. Frontiers in Endocrinology, 2021, 12, 690387.	3.5	2
30	Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer. International Journal of Molecular Sciences, 2021, 22, 8340.	4.1	42
31	Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1. Cancers, 2021, 13, 4079.	3.7	6
32	The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus. Cellular and Molecular Life Sciences, 2021, 78, 6963-6978.	5.4	11
33	Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor. Biochemical Pharmacology, 2021, 192, 114715.	4.4	5
34	Pharmacological and structure-activity relationship studies of oleoyl-lysophosphatidylinositol synthetic mimetics. Pharmacological Research, 2021, 172, 105822.	7.1	4
35	GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. ACS Pharmacology and Translational Science, 2021, 4, 296-313.	4.9	24
36	Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes. Frontiers in Cell and Developmental Biology, 2021, 9, 749607.	3.7	12

#	Article	IF	Citations
37	Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro. Communications Biology, 2021, 4, 1347.	4.4	29
38	Novel agonistâ€•and antagonistâ€based radioligands for the GLPâ€2 receptor â€•useful tools for studies of basic GLPâ€2R pharmacology. British Journal of Pharmacology, 2021, , .	5.4	5
39	G proteinâ€coupled receptor pharmacologyâ€”The next generation. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 3-4.	2.5	2
40	Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and longâ€term impairment of the GIP system. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 122-132.	2.5	27
41	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61
42	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH2. Bone, 2020, 130, 115079.	2.9	20
43	Molecular interactions of full-length and truncated GIP peptides with the GIP receptor â€“ A comprehensive review. Peptides, 2020, 125, 170224.	2.4	27
44	Recent advances of GIP and future horizons. Peptides, 2020, 125, 170230.	2.4	21
45	GPR183 Regulates Interferons, Autophagy, and Bacterial Growth During Mycobacterium tuberculosis Infection and Is Associated With TB Disease Severity. Frontiers in Immunology, 2020, 11, 601534.	4.8	25
46	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	2.9	25
47	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles. Nature Communications, 2020, 11, 4033.	12.8	46
48	Methods for Studying Endocytotic Pathways of Herpesvirus Encoded G Protein-Coupled Receptors. Molecules, 2020, 25, 5710.	3.8	4
49	Three-Dimensional Explant Platform for Studies on Choroid Plexus Epithelium. Frontiers in Cellular Neuroscience, 2020, 14, 108.	3.7	5
50	GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2710-e2716.	3.6	97
51	Perspective: Implications of Ligandâ€“Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors. ACS Pharmacology and Translational Science, 2020, 3, 179-189.	4.9	31
52	G Protein-Coupled Receptors in the Sweet Spot: Glycosylation and other Post-translational Modifications. ACS Pharmacology and Translational Science, 2020, 3, 237-245.	4.9	41
53	The European Research Network on Signal Transduction (ERNEST): Toward a Multidimensional Holistic Understanding of G Protein-Coupled Receptor Signaling. ACS Pharmacology and Translational Science, 2020, 3, 361-370.	4.9	15
54	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	3.6	37

#	Article	IF	Citations
55	Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21. Biochemistry, 2020, 59, 1338-1350.	2.5	11
56	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidismâ€"A Randomized Crossover Study. Journal of Bone and Mineral Research, 2020, 36, 1448-1458.	2.8	17
57	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020, 5, .	5.0	177
58	Physiology of the Incretin Hormones,<scp>GIP</scp>and<scp>GLP</scp>â€1â€"Regulation of Release and Posttranslational Modifications. , 2019, 9, 1339-1381.		38
59	Arrestinâ€independent constitutive endocytosis of GPR125/ADGRA3. Annals of the New York Academy of Sciences, 2019, 1456, 186-199.	3.8	21
60	Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats. Frontiers in Endocrinology, 2019, 10, 492.	3.5	21
61	Structure-function guided modeling of chemokine-GPCR specificity for the chemokine XCL1 and its receptor XCR1. Science Signaling, 2019, 12, .	3.6	16
62	Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1081-E1093.	3.5	32
63	Development of highly efficient protocols for extraction and amplification of cytomegalovirus DNA from dried blood spots for detection and genotyping of polymorphic immunomodulatory genes. PLoS ONE, 2019, 14, e0222053.	2.5	4
64	Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7. Frontiers in Immunology, 2019, 10, 2156.	4.8	18
65	Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation. MBio, 2019, 10, .	4.1	18
66	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	2.9	45
67	Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Frontiers in Endocrinology, 2019, 10, 75.	3.5	70
68	Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E660-E673.	3.5	26
69	Rat Cytomegalovirus-encoded Î³-chemokine vXCL1 is a highly adapted, species-specific agonist for rat XCR1+ dendritic cells. Journal of Cell Science, 2019, 133, .	2.0	5
70	A Pilot Study Showing Acute Inhibitory Effect of GLPâ€1 on the Bone Resorption Marker CTX in Humans. JBMR Plus, 2019, 3, e10209.	2.7	19
71	Selective Allosteric Modulation of N-Terminally Cleaved, but Not Full Length CCL3 in CCR1. ACS Pharmacology and Translational Science, 2019, 2, 429-441.	4.9	3
72	Neuromedin U Does Not Act as a Decretin in Rats. Cell Metabolism, 2019, 29, 719-726.e5.	16.2	9

#	Article	IF	Citations
73	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.6	118
74	1976-P: Physiological Effects of GIP(1-30)NH2 in Healthy Subjects. Diabetes, 2019, 68, 1976-P.	0.6	1
75	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
76	Inhibition of HIV Fusion by Small Molecule Agonists through Efficacy-Engineering of CXCR4. ACS Chemical Biology, 2018, 13, 881-886.	3.4	11
77	Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochemical Pharmacology, 2018, 150, 97-107.	4.4	65
78	Glucoseâ€lowering effects and mechanisms of the bile acidâ€sequestering resin sevelamer. Diabetes, Obesity and Metabolism, 2018, 20, 1623-1631.	4.4	21
79	Synthesis and in Vitro Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists. ACS Medicinal Chemistry Letters, 2018, 9, 496-501.	2.8	9
80	Oxyntomodulin: Actions and role in diabetes. Peptides, 2018, 100, 48-53.	2.4	59
81	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	2.4	56
82	Development of potent and proteolytically stable human neuromedin U receptor agonists. European Journal of Medicinal Chemistry, 2018, 144, 887-897.	5.5	13
83	Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Molecular Metabolism, 2018, 11, 84-95.	6.5	135
84	Biased signaling of G protein-coupled receptors â€“ From a chemokine receptor CCR7 perspective. General and Comparative Endocrinology, 2018, 258, 4-14.	1.8	25
85	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	6.3	66
86	Dual treatment with a fixed ratio of glucagon and insulin increases the therapeutic window of insulin in diabetic rats. Physiological Reports, 2018, 6, e13657.	1.7	6
87	Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. Nutrition and Diabetes, 2018, 8, 2.	3.2	10
88	Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity. Frontiers in Immunology, 2018, 9, 1933.	4.8	5
89	Insulin Secretion Depends on Intra-islet Glucagon Signaling. Cell Reports, 2018, 25, 1127-1134.e2.	6.4	233
90	CCL19 with CCL21-tail displays enhanced glycosaminoglycan binding with retained chemotactic potency in dendritic cells. Journal of Leukocyte Biology, 2018, 104, 401-411.	3.3	20

#	Article	IF	Citations
91	The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. American Journal of Physiology - Renal Physiology, 2018, 315, G53-G65.	3.4	235
92	Mutational analysis of CCL20 reveals flexibility of N-terminal amino acid composition and length. Journal of Leukocyte Biology, 2018, 104, 423-434.	3.3	6
93	Ligand-selective small molecule modulators of the constitutively active vGPCR US28. European Journal of Medicinal Chemistry, 2018, 155, 244-254.	5.5	10
94	Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 1132-1141.	2.4	16
95	Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats. PLoS ONE, 2018, 13, e0194468.	2.5	7
96	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.6	3
97	Viral GPCR US28 can signal in response to chemokine agonists of nearly unlimited structural degeneracy. ELife, 2018, 7, .	6.0	41
98	The Gî²î³â€subunit interacts directly with aquaporinâ€2 (AQP2) and regulates its membrane targeting. FASEB Journal, 2018, 32, 747.3.	0.5	0
99	Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4). Bioorganic and Medicinal Chemistry, 2017, 25, 646-657.	3.0	6
100	Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. Biochemical Pharmacology, 2017, 132, 92-101.	4.4	42
101	Biased agonism and allosteric modulation of G proteinâ€coupled receptor 183 â€“ a 7TM receptor also known as Epsteinâ€“Barr virusâ€induced gene 2. British Journal of Pharmacology, 2017, 174, 2031-2042.	5.4	13
102	EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemiaâ€“like B-cell malignancies. Blood, 2017, 129, 866-878.	1.4	14
103	Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial. Journal of Cardiovascular Translational Research, 2017, 10, 470-479.	2.4	32
104	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	6.4	28
105	The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes, 2017, 66, 2363-2371.	0.6	88
106	Structureâ€based discovery of novel US28 small molecule ligands with different modes of action. Chemical Biology and Drug Design, 2017, 89, 289-296.	3.2	10
107	Signaling via G proteins mediates tumorigenic effects of GPR87. Cellular Signalling, 2017, 30, 9-18.	3.6	21
108	Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells. Journal of Immunology Research, 2017, 2017, 1-12.	2.2	22

#	Article	IF	Citations
109	Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathogens, 2017, 13, e1006346.	4.7	19
110	Probing Biased Signaling in Chemokine Receptors. Methods in Enzymology, 2016, 570, 155-186.	1.0	22
111	Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. Frontiers in Immunology, 2016, 7, 568.	4.8	59
112	Pharmacokinetics of highâ€dose intravenous melatonin in humans. Journal of Clinical Pharmacology, 2016, 56, 324-329.	2.0	44
113	Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5). Journal of Biological Chemistry, 2016, 291, 26860-26874.	3.4	11
114	Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochemical Pharmacology, 2016, 119, 66-75.	4.4	40
115	Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21. Cytotherapy, 2016, 18, 1187-1196.	0.7	18
116	Attenuation of chemokine receptor function and surface expression as an immunomodulatory strategy employed by human cytomegalovirus is linked to vGPCR US28. Cell Communication and Signaling, 2016, 14, 31.	6.5	10
117	In vivo and in vitro degradation of peptide YY_{3â€“36} to inactive peptide YY_{3â€“34} in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R866-R874.	1.8	46
118	Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule Binding. Journal of Biological Chemistry, 2016, 291, 16208-16220.	3.4	11
119	The future of antiviral immunotoxins. Journal of Leukocyte Biology, 2016, 99, 911-925.	3.3	24
120	Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3. Journal of Medicinal Chemistry, 2016, 59, 2222-2243.	6.4	19
121	Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacology & Toxicology, 2016, 17, 8.	2.4	121
122	Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo. Oncotarget, 2016, 7, 62439-62459.	1.8	32
123	Vasopressin receptors V1_aand V2 are not osmosensors. Physiological Reports, 2015, 3, e12519.	1.7	6
124	Identification and Functional Comparison of Seven-Transmembrane G-Protein-Coupled BILF1 Receptors in Recently Discovered Nonhuman Primate Lymphocryptoviruses. Journal of Virology, 2015, 89, 2253-2267.	3.4	19
125	EBV, the Human Host, and the 7TM Receptors. Progress in Molecular Biology and Translational Science, 2015, 129, 395-427.	1.7	11
126	The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine. Peptides, 2015, 67, 20-28.	2.4	40

#	Article	IF	Citations
127	Probing the Molecular Interactions between CXC Chemokine Receptor 4 (CXCR4) and an Arginine-Based Tripeptidomimetic Antagonist (KRH-1636). Journal of Medicinal Chemistry, 2015, 58, 8141-8153.	6.4	14
128	Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists. Future Medicinal Chemistry, 2015, 7, 1261-1283.	2.3	11
129	Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8427-8432.	7.1	43
130	The anorexic hormone Peptide YY₃₋₃₆is rapidly metabolized to inactive Peptide YY₃₋₃₄inÂvivo. Physiological Reports, 2015, 3, e12455.	1.7	23
131	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. Diabetes, 2015, 64, 72-78.	0.6	60
132	Biased and G Protein-Independent Signaling of Chemokine Receptors. Frontiers in Immunology, 2014, 5, 277.	4.8	152
133	Oxysterolâ€EBI2 signaling in immune regulation and viral infection. European Journal of Immunology, 2014, 44, 1904-1912.	2.9	35
134	Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2. Molecular Pharmacology, 2014, 86, 358-368.	2.3	35
135	Identification and Characterization of Small Molecule Modulators of the Epsteinâ€“Barr Virus-Induced Gene 2 (EBI2) Receptor. Journal of Medicinal Chemistry, 2014, 57, 3358-3368.	6.4	49
136	International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacological Reviews, 2014, 66, 1-79.	16.0	735
137	Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4). Bioorganic and Medicinal Chemistry, 2014, 22, 4759-4769.	3.0	16
138	Functional Properties of Virus-Encoded and Virus-Regulated G Protein-Coupled Receptors. Methods in Pharmacology and Toxicology, 2014, , 45-65.	0.2	3
139	Interaction of Chemokines with their Receptors â€“ From Initial Chemokine Binding to Receptor Activating Steps. Current Medicinal Chemistry, 2014, 21, 3594-3614.	2.4	44
140	Small molecule antagonism of oxysterolâ€induced Epsteinâ€“Barr virus induced gene 2 (EBI2) activation. FEBS Open Bio, 2013, 3, 156-160.	2.3	30
141	Extracellular Disulfide Bridges Serve Different Purposes in Two Homologous Chemokine Receptors, CCR1 and CCR5. Molecular Pharmacology, 2013, 84, 335-345.	2.3	18
142	Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7. Journal of Biological Chemistry, 2013, 288, 12511-12521.	3.4	59
143	Molecular Characterization of Oxysterol Binding to the Epstein-Barr Virus-induced Gene 2 (GPR183). Journal of Biological Chemistry, 2012, 287, 35470-35483.	3.4	46
144	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides, 2012, 179, 91-100.	1.9	81

#	Article	IF	Citations
145	GPR119 as a fat sensor. Trends in Pharmacological Sciences, 2012, 33, 374-381.	8.7	165
146	Modulation in Selectivity and Allosteric Properties of Small-Molecule Ligands for CC-Chemokine Receptors. Journal of Medicinal Chemistry, 2012, 55, 8164-8177.	6.4	27
147	2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1409-E1417.	3.6	238
148	Ligand Modulation of the Epstein-Barr Virus-induced Seven-transmembrane Receptor EBI2. Journal of Biological Chemistry, 2011, 286, 29292-29302.	3.4	41
149	Allosteric and Orthosteric Sites in CC Chemokine Receptor (CCR5), a Chimeric Receptor Approach. Journal of Biological Chemistry, 2011, 286, 37543-37554.	3.4	41
150	The E92K Melanocortin 1 Receptor Mutant Induces cAMP Production and Arrestin Recruitment but Not ERK Activity Indicating Biased Constitutive Signaling. PLoS ONE, 2011, 6, e24644.	2.5	27
151	EBI2, GPR18, and GPR17 â€“ Three Structurally Related but Biologically Distinct 7TM Receptors. Current Topics in Medicinal Chemistry, 2011, 11, 618-628.	2.1	10
152	The minor binding pocket: a major player in 7TM receptor activation. Trends in Pharmacological Sciences, 2010, 31, 567-574.	8.7	99
153	Ligand binding and micro-switches in 7TM receptor structures. Trends in Pharmacological Sciences, 2009, 30, 249-259.	8.7	310
154	Positive Versus Negative Modulation of Different Endogenous Chemokines for CC-chemokine Receptor 1 by Small Molecule Agonists through Allosteric Versus Orthosteric Binding. Journal of Biological Chemistry, 2008, 283, 23121-23128.	3.4	42
155	Structural Motifs of Importance for the Constitutive Activity of the Orphan 7TM Receptor EBI2: Analysis of Receptor Activation in the Absence of an Agonist. Molecular Pharmacology, 2008, 74, 1008-1021.	2.3	32
156	Kaposi Sarcoma-associated Herpes Virus Targets the Lymphotactin Receptor with Both a Broad Spectrum Antagonist vCCL2 and a Highly Selective and Potent Agonist vCCL3. Journal of Biological Chemistry, 2007, 282, 17794-17805.	3.4	38
157	Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8. Molecular Pharmacology, 2007, 72, 327-340.	2.3	47
158	Activation of the CXCR3 Chemokine Receptor through Anchoring of a Small Molecule Chelator Ligand between TM-III, -IV, and -VI. Molecular Pharmacology, 2007, 71, 930-941.	2.3	40
159	Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor. Journal of Biological Chemistry, 2007, 282, 27354-27365.	3.4	104
160	Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8. Molecular Pharmacology, 2007, 72, 327-340.	2.3	17
161	MOLECULAR MECHANISM OF 7TM RECEPTOR ACTIVATIONâ€"A GLOBAL TOGGLE SWITCH MODEL. Annual Review of Pharmacology and Toxicology, 2006, 46, 481-519.	9.4	382
162	Targeting Herpesvirus Reliance of the Chemokine System. Current Drug Targets, 2006, 7, 103-118.	2.1	20

#	Article	IF	Citations
163	GIP-(3â€“42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E468-E475.	3.5	54
164	Prohormone Convertase 1/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor. Journal of Biological Chemistry, 2006, 281, 11050-11057.	3.4	92
165	Conformational Constraining of Inactive and Active States of a Seven Transmembrane Receptor by Metal Ion Site Engineering in the Extracellular End of Transmembrane Segment V. Molecular Pharmacology, 2006, 70, 1892-1901.	2.3	14
166	Molecular Pharmacological Phenotyping of EBI2. Journal of Biological Chemistry, 2006, 281, 13199-13208.	3.4	98
167	GluVII:06 - A Highly Conserved and Selective Anchor Point for Non-Peptide Ligands in Chemokine Receptors. Current Topics in Medicinal Chemistry, 2006, 6, 1319-1333.	2.1	60
168	AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochemical Pharmacology, 2005, 70, 752-761.	4.4	122
169	Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor. Journal of Virology, 2005, 79, 536-546.	3.4	118
170	High Constitutive Activity of a Virus-Encoded Seven Transmembrane Receptor in the Absence of the Conserved DRY Motif (Asp-Arg-Tyr) in Transmembrane Helix 3. Molecular Pharmacology, 2005, 68, 11-19.	2.3	60
171	Virus-encoded chemokine receptors â€“ putative novel antiviral drug targets. Neuropharmacology, 2005, 48, 1-13.	4.1	33
172	Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor. Journal of Biological Chemistry, 2004, 279, 3033-3041.	3.4	204
173	Identification of a Novel Site within G Protein Îł Subunits Important for Specificity of Receptor-G Protein Interaction. Molecular Pharmacology, 2004, 66, 250-259.	2.3	50
174	The CXC Chemokine Receptor Encoded by Herpesvirus saimiri, ECRF3, Shows Ligand-regulated Signaling through Gi, Gq, and G12/13 Proteins but Constitutive Signaling Only through Gi and G12/13 Proteins. Journal of Biological Chemistry, 2004, 279, 32524-32533.	3.4	49
175	Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74. Virology, 2004, 325, 241-251.	2.4	83
176	Virally encoded 7TM receptors. Oncogene, 2001, 20, 1582-1593.	5.9	92
177	Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. Journal of Clinical Investigation, 2001, 108, 1789-1796.	8.2	95
178	Selective Elimination of High Constitutive Activity or Chemokine Binding in the Human Herpesvirus 8 Encoded Seven Transmembrane Oncogene ORF74. Journal of Biological Chemistry, 2000, 275, 26309-26315.	3.4	56
179	Agonists and Inverse Agonists for the Herpesvirus 8-encoded Constitutively Active Seven-transmembrane Oncogene Product, ORF-74. Journal of Biological Chemistry, 1999, 274, 956-961.	3.4	169
180	Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3receptor. FEBS Letters, 1998, 439, 35-40.	2.8	36

#	Article	IF	Citations
181	Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Letters, 1998, 441, 209-214.	2.8	191
182	Phorbol Esters and SDF-1 Induce Rapid Endocytosis and Down Modulation of the Chemokine Receptor CXCR4. Journal of Cell Biology, 1997, 139, 651-664.	5.2	357
183	Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist. Science, 1997, 276, 276-279.	12.6	654
184	A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus. Science, 1997, 277, 1656-1659.	12.6	473
185	The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection. Frontiers in Endocrinology, 0, 13, .	3.5	1
186	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.6	1